Pages that link to "Q44272543"
Jump to navigation
Jump to search
The following pages link to Prognostic or predictive plasma cytokines and angiogenic factors for patients treated with pazopanib for metastatic renal-cell cancer: a retrospective analysis of phase 2 and phase 3 trials (Q44272543):
Displaying 50 items.
- Trial Watch (Q24618653) (← links)
- Cytokine patterns in cancer patients: A review of the correlation between interleukin 6 and prognosis (Q26741263) (← links)
- Homogeneous Biosensing Based on Magnetic Particle Labels (Q26747505) (← links)
- Current management and future directions in the treatment of advanced renal cell carcinoma-a latin american perspective: 10 years in review (Q26774515) (← links)
- Pazopanib in sarcomas: expanding the PALETTE (Q26825050) (← links)
- Molecular marker for predicting treatment response in advanced renal cell carcinoma: does the promise fulfill clinical need? (Q26825512) (← links)
- Profile of pazopanib and its potential in the treatment of epithelial ovarian cancer (Q27011840) (← links)
- Individualising treatment choices in a crowded treatment algorithm (Q27023669) (← links)
- Predictive and prognostic biomarkers of targeted agents and modern immunotherapy in renal cell carcinoma (Q28067482) (← links)
- miR-200c Regulation of Metastases in Ovarian Cancer: Potential Role in Epithelial and Mesenchymal Transition (Q28071987) (← links)
- Monitoring of the Immune Dysfunction in Cancer Patients (Q28072712) (← links)
- Renal cell carcinoma (Q30235364) (← links)
- Analysis of plasma cytokines and angiogenic factors in patients with pretreated urothelial cancer receiving Pazopanib: the role of circulating interleukin-8 to enhance the prognostic accuracy (Q30563774) (← links)
- A five-factor biomarker profile obtained week 4-12 of treatment for improved prognostication in metastatic renal cell carcinoma: Results from DARENCA study 2. (Q33426559) (← links)
- Sunitinib-associated hypertension and neutropenia as efficacy biomarkers in metastatic renal cell carcinoma patients (Q33426958) (← links)
- Therapeutic potential of TAS-115 via c-MET and PDGFRα signal inhibition for synovial sarcoma (Q33696791) (← links)
- Genetic modulation of the interleukin 6 (IL-6) system in patients with advanced gastric cancer: a background for an alternative target therapy. (Q33714950) (← links)
- Anti-angiogenic therapy for cancer: current progress, unresolved questions and future directions (Q33770680) (← links)
- High EphA2 protein expression in renal cell carcinoma is associated with a poor disease outcome (Q33844126) (← links)
- Modulation of circulating protein biomarkers following TRC105 (anti-endoglin antibody) treatment in patients with advanced cancer. (Q33913556) (← links)
- Phase I study of capecitabine, oxaliplatin, bevacizumab, and everolimus in advanced solid tumors (Q33921891) (← links)
- Adjusting for misclassification in a stratified biomarker clinical trial. (Q33934232) (← links)
- Lenvatinib, an angiogenesis inhibitor targeting VEGFR/FGFR, shows broad antitumor activity in human tumor xenograft models associated with microvessel density and pericyte coverage (Q34144848) (← links)
- Investigation of novel circulating proteins, germ line single-nucleotide polymorphisms, and molecular tumor markers as potential efficacy biomarkers of first-line sunitinib therapy for advanced renal cell carcinoma (Q34243444) (← links)
- Granulocyte macrophage colony-stimulating factor as a predictor of the response of metastatic renal cell carcinoma to tyrosine kinase inhibitor therapy (Q34265694) (← links)
- Serum protein profiling reveals baseline and pharmacodynamic biomarker signatures associated with clinical outcome in mCRC patients treated with chemotherapy ± cediranib (Q34354522) (← links)
- The current status of tailor-made medicine with molecular biomarkers for patients with clear cell renal cell carcinoma (Q34365135) (← links)
- Prognostic and predictive blood-based biomarkers in patients with advanced pancreatic cancer: results from CALGB80303 (Alliance) (Q34447921) (← links)
- Biomarkers for anti-angiogenic therapy in cancer. (Q34695003) (← links)
- Sites of disease as predictors of outcome in metastatic renal cell carcinoma patients treated with first-line sunitinib or sorafenib (Q35214229) (← links)
- IL8 polymorphisms and overall survival in pazopanib- or sunitinib-treated patients with renal cell carcinoma (Q35274936) (← links)
- Circulating cytokines and monocyte subpopulations as biomarkers of outcome and biological activity in sunitinib-treated patients with advanced neuroendocrine tumours (Q35274974) (← links)
- Carbonic anhydrase 9 expression increases with vascular endothelial growth factor-targeted therapy and is predictive of outcome in metastatic clear cell renal cancer. (Q35540063) (← links)
- Immunological response and overall survival in a subset of advanced renal cell carcinoma patients from a randomized phase 2/3 study of naptumomab estafenatox plus IFN-α versus IFN-α. (Q35552042) (← links)
- CECs and IL-8 Have Prognostic and Predictive Utility in Patients with Recurrent Platinum-Sensitive Ovarian Cancer: Biomarker Correlates from the Randomized Phase-2 Trial of Olaparib and Cediranib Compared with Olaparib in Recurrent Platinum-Sensitiv (Q35669792) (← links)
- High expression of interleukin-11 is an independent indicator of poor prognosis in clear-cell renal cell carcinoma (Q35674197) (← links)
- Trial Watch: Therapeutic vaccines in metastatic renal cell carcinoma (Q35799377) (← links)
- Carbonic anhydrase IX as a potential biomarker of efficacy in metastatic clear-cell renal cell carcinoma patients receiving sorafenib or placebo: analysis from the treatment approaches in renal cancer global evaluation trial (TARGET). (Q35909843) (← links)
- Hypertension and Circulating Cytokines and Angiogenic Factors in Patients With Advanced Non-Clear Cell Renal Cell Carcinoma Treated With Sunitinib: Results From a Phase II Trial (Q36116324) (← links)
- Association of single nucleotide polymorphisms in IL8 and IL13 with sunitinib-induced toxicity in patients with metastatic renal cell carcinoma. (Q36275134) (← links)
- The sum of gains and losses of genes encoding the protein tyrosine kinase targets predicts response to multi-kinase inhibitor treatment: Characterization, validation, and prognostic value (Q36413467) (← links)
- Biomarkers for tyrosine kinase inhibitors in renal cell cancer (Q36450612) (← links)
- Prognostic Biomarkers for Response to Vascular Endothelial Growth Factor-Targeted Therapy for Renal Cell Carcinoma. (Q36893510) (← links)
- Precision Oncology: Identifying Predictive Biomarkers for the Treatment of Metastatic Renal Cell Carcinoma (Q37179808) (← links)
- Soluble FAS ligand as a biomarker of disease recurrence in differentiated thyroid cancer (Q37237661) (← links)
- Prognostic/predictive value of 207 serum factors in colorectal cancer treated with cediranib and/or chemotherapy (Q37352578) (← links)
- Prognostic factors associated with the response to sunitinib in patients with metastatic renal cell carcinoma (Q37364606) (← links)
- Clinical and biomarker outcomes of the phase II vandetanib study from the BATTLE trial (Q37428434) (← links)
- Statistical and practical considerations for clinical evaluation of predictive biomarkers (Q37463622) (← links)
- Tumour angiogenesis regulation by the miR-200 family (Q37523569) (← links)